Confronto
Octreotide vs. Bremelanotide
Due peptidi a confronto — identità, base di evidenze, stato legale ed eventi avversi noti.
Identità
Categoria
Ricerca (altro)
Ricerca (altro)
N. CAS
83150-76-9
189691-06-3
Peso molecolare
1019.24 g/mol
1025.18 g/mol
Emivita
1.7 h
2.7 h
Sequenza
D-Phe-Cys-Phe-D-Trp-Lys-Thr-Cys-Thr(ol)Ac-Nle-c[Asp-His-D-Phe-Arg-Trp-Lys]-OHMeccanismo d'azione
Octreotide
Octreotide is a cyclic octapeptide that selectively binds somatostatin-receptor subtypes SSTR2 and SSTR5. Via G-protein-coupled signalling, adenylyl cyclase is inhibited, reducing the secretion of multiple hormones (growth hormone, IGF-1, glucagon, insulin, VIP, serotonin). Structural stabilisation via a disulfide bridge and D-amino acids extends the half-life relative to natural somatostatin (minutes to several hours).
Bremelanotide
Bremelanotide is a cyclic peptide that binds non-selectively to melanocortin receptors (MC1R through MC5R) — with highest affinity at MC4R in the central nervous system. The precise role of MC4R activation in sexual behaviour is not fully understood; animal data show effects on hypothalamic circuits. Peripheral effects (blood pressure, hyperpigmentation) are attributed to MC1R/MC2R.
Base di evidenze
Evidenza più alta
RCT sull'uomo
RCT sull'uomo
Studi
5
5
di cui sull'uomo
4
5
Effetti registrati
3
3
Contraddizioni aperte
1
1
Eventi avversi documentati
2
2
Stato legale
Voci complete
Frequently asked questions
- What is the difference between Octreotide and Bremelanotide?
- Octreotide is classified as "Ricerca (altro)", while Bremelanotide is classified as "Ricerca (altro)". Octreotide: Synthetic octapeptide somatostatin analog with a longer half-life than endogenous somatostatin. FDA- and EMA-approved since the 1980s for acromegaly and neuroendocrine tumours. Bremelanotide: Synthetic cyclic heptapeptide acting as a non-selective melanocortin-receptor agonist. FDA-approved in 2019 as Vyleesi for hypoactive sexual desire disorder (HSDD) in pre-menopausal women. This page contrasts both neutrally and source-based — with no usage or dosing recommendation.
- Which peptide is better supported by science, Octreotide or Bremelanotide?
- The highest available evidence level is "RCT sull'uomo" for Octreotide and "RCT sull'uomo" for Bremelanotide. A higher evidence level means more robust data, but says nothing about suitability for an individual. The full body of evidence is on each peptide's own page.
- What is the legal status of Octreotide and Bremelanotide in Germany and the United States?
- Germania: Octreotide — Su prescrizione, Bremelanotide — Non approvato. Stati Uniti: Octreotide — Su prescrizione, Bremelanotide — Su prescrizione. These are factual summaries with source and review date on the individual pages.